Abstract
Introduction:
Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.
Patients and methods:
Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy.
Results:
Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay.
Conclusions:
Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.
Keywords:
Afatinib; EGFR; Non-small cell lung cancer.
Copyright © 2014 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adult
-
Afatinib
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / enzymology
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Disease-Free Survival
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / genetics
-
ErbB Receptors / metabolism
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / enzymology
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Mutation
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolines / administration & dosage
-
Quinazolines / adverse effects
-
Quinazolines / therapeutic use*
-
Retrospective Studies
-
Time Factors
-
Treatment Outcome
-
United Kingdom
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
Afatinib
-
EGFR protein, human
-
ErbB Receptors